SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hagiwara Akifumi)
 

Sökning: WFRF:(Hagiwara Akifumi) > Incidence, molecula...

  • Hagiwara, AkifumiUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan (författare)

Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-07-17
  • Springer,2022
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-198305
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-198305URI
  • https://doi.org/10.1007/s11060-022-04088-3DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Purpose: Pseudoprogression (PsP) remains an elusive and clinically important, yet ill-defined, phenomena that, generally, involves a period of early radiographic progression (enhancement) followed by a period of radiographic stability or regression. In the current study, we utilized data from the control arm of a phase III clinical trial in newly-diagnosed glioblastoma to explore imaging characteristics of “clinically-defined PsP”, or early radiographic progression (PFS < 6 months from chemoradiation) followed by a long post-progression residual overall survival (ROS > 12 months).Methods: One hundred sixty-nine patients with newly-diagnosed GBM from the control arm of the AVAglio trial (NCT00943826) who presented with early radiographic progressive disease (PD) (< 6 months) were included. Clinical characteristics, topographical patterns, and radiomic features were compared between newly-diagnosed GBM exhibiting early PD and early death (< 12-month ROS, “true PD”) with those exhibiting early PD and a long residual survival (> 12-month ROS, “clinically-defined PsP”).Results: “Clinically-defined PsP” occurred to 38.5% of patients with early PD, and was more associated with MGMT methylation (P = 0.02), younger age (P = 0.003), better neurological performance (P = 0.01), and lower contrast-enhancing tumor volume (P = 0.002) at baseline. GBM showing “true PD” occurred more frequently in the right internal capsule, thalamus, lentiform nucleus, and temporal lobe than those with “clinical PsP”. Radiomic analysis predicted “clinical PsP” with > 70% accuracy on the validation dataset.Conclusion: Patients with early PD that eventually exhibit “clinically-defined PsP” have distinct clinical, molecular, and MRI characteristics. This information may be useful for treating clinicians to better understand the potential risks and outcome in patients exhibiting early radiographic changes following chemoradiation.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Schlossman, JacobUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States (författare)
  • Shabani, SoroushUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States (författare)
  • Raymond, CatalinaUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States (författare)
  • Tatekawa, HiroyukiUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, Osaka, Japan (författare)
  • Abrey, Lauren E.F. Hoffman-La Roche, Ltd., Basel, Switzerland (författare)
  • Garcia, JosepF. Hoffman-La Roche, Ltd., Basel, Switzerland (författare)
  • Chinot, OlivierAix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (författare)
  • Saran, FrankThe Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (författare)
  • Nishikawa, RyoSaitama Medical University, Saitama, Japan (författare)
  • Henriksson, RogerUmeå universitet,Onkologi,Regional Cancer Center Stockholm, Stockholm, Sweden(Swepub:umu)rohe0003 (författare)
  • Mason, Warren P.Princess Margaret Hospital, Toronto, Canada (författare)
  • Wick, WolfgangClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (författare)
  • Cloughesy, Timothy F.UCLA Brain Research Institute (BRI), David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States (författare)
  • Ellingson, Benjamin M.UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; UCLA Brain Research Institute (BRI), David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, CA, Los Angeles, United States; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States (författare)
  • UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Radiology, Juntendo University School of Medicine, Tokyo, JapanUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Neuro-Oncology: Springer159, s. 509-5180167-594X1573-7373

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy